You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database

Citation Tools

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - non-biologic treatment and small molecules
AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Harnett J, Gerber R, Gruben D, et al
AB0399 Real-World Experience with Tofacitinib vs Adalimumab (ADA), Etanercept (ETN) and Abatacept (ABA) in Biologic-Experienced Patients with Rheumatoid Arthritis (RA): Data from A US Administrative Claims Database
Annals of the Rheumatic Diseases 2016;75:1042-1043.